U.S. Retail Distributors Stock News

Compugen (CGEN) has just reported its FY 2025 results, with Q3 revenue of US$1.9 million and a basic EPS loss of US$0.07. Trailing twelve month figures show revenue of US$6.9 million and a basic EPS loss of US$0.30. The company has seen quarterly revenue range from US$1.3 million to US$2.3 million in FY 2025 so far, with basic EPS losses between US$0.07 and US$0.08 over the same stretch. This sets up a picture in which top line consistency still sits alongside negative earnings. With revenue...

If you are wondering whether Realty Income is fairly priced at its current level, this article explains how its market value compares with several valuation checks. With the share price at US$67.56 and returns of 1.3% over 7 days, 10.5% over 30 days, 17.9% year to date, 24.1% over 1 year, 24.1% over 3 years and 48.6% over 5 years, many investors are reassessing what they are willing to pay for the stock. Recent attention on Realty Income has centered on its role as a large US REIT for...

Enterprise Products Partners (EPD) is back in focus after quarterly results that exceeded revenue and EBITDA expectations. The company also announced new infrastructure projects and received positive analyst commentary tied to its long distribution track record and disciplined balance sheet. See our latest analysis for Enterprise Products Partners. The latest quarterly beat and a full pipeline of growth projects have coincided with a solid 11.15% 1 month share price return and a 15.32% 3...

Why PYRUKYND’s UAE approval is drawing fresh attention to Agios Pharmaceuticals The recent approval of PYRUKYND (mitapivat) in the United Arab Emirates for certain thalassemia patients gives Agios Pharmaceuticals (AGIO) a new commercial foothold in the Gulf region and a fresh catalyst for investor interest. See our latest analysis for Agios Pharmaceuticals. Investors have been reacting to a mix of clinical milestones and events such as Agios’ upcoming presentation at the TD Cowen Health Care...

Red Rock Resorts (RRR) has drawn attention after recent share performance, with a 1 day return of negative 3.15% and mixed moves over the past week, month and past 3 months. See our latest analysis for Red Rock Resorts. That 1 day share price decline and softer 30 day share price return sit alongside a 2.26% 3 month share price gain and a much stronger 1 year total shareholder return of 30.46%. This suggests that longer term momentum has been more positive than the very recent trading...

Why Northrop Grumman stock is on investors’ radar Northrop Grumman (NOC) has drawn attention recently as investors weigh its current valuation against its track record of revenue and net income growth, along with strong multi year total returns. See our latest analysis for Northrop Grumman. At a share price of US$724.38, Northrop Grumman has recently seen a 1 day share price return of 1.9% and a 30 day share price return of 4.6%. Its 1 year total shareholder return of 55.5% and 5 year total...

What Hinge Health’s latest trading move signals for investors Hinge Health (HNGE) has caught investor attention after a recent move in its share price, with the stock closing at US$42.76 as short term returns and fundamentals offer a mixed picture. See our latest analysis for Hinge Health. The recent 7 day share price return of 11.21% and 30 day share price return of 22.52% sit against a weaker 90 day share price return of 8.16% and year to date share price return of 6.15%. This suggests...

Ascendis Pharma (NasdaqGS:ASND) is in focus after the U.S. FDA granted accelerated approval for YUVIWEL, a once weekly treatment for children with achondroplasia, along with a Rare Pediatric Disease Priority Review Voucher. See our latest analysis for Ascendis Pharma. The FDA approval, Rare Pediatric Disease Priority Review Voucher and upcoming conference appearance at the TD Cowen Health Care Conference come alongside a 1 year total shareholder return of 59.34% and a 3 month share price...

Kaspi.kz has reported past fourth-quarter 2025 results, with revenue of KZT 1,145,548 million up from KZT 730,351 million a year earlier, while net income eased to KZT 276,983 million from KZT 316,401 million. Alongside this, the company is pushing new payment technology such as its Kaspi Alakan ‘Pay by Palm’ biometric system and reiterating its focus on value-added services and the Hepsiburada integration. We’ll now examine how Kaspi.kz’s strong revenue growth alongside its Kaspi Alakan...

The Cheesecake Factory reported past fourth-quarter 2025 sales of US$961.56 million versus US$920.96 million a year earlier, while net income fell to US$28.78 million from US$41.15 million, and full-year 2025 sales rose to US$3.75 billion as net income eased to US$148.43 million from US$156.78 million. Alongside these mixed results, the company raised its quarterly cash dividend to US$0.30 per share and continued repurchasing stock, indicating an ongoing commitment to returning capital to...

In late February 2026, Strategic Education, Inc. reported fourth-quarter 2025 results showing revenue of US$323.21 million and net income of US$37.91 million, alongside a quarterly dividend of US$0.60 per share and completion of a long-running share repurchase authorization. The company’s earnings per share rose meaningfully year on year and were aided by AI-enabled productivity gains and strong growth in its higher-margin Education Technology Services segment, which together improved...

RLJ Lodging Trust (RLJ) shares are in focus after the company posted above-consensus fourth quarter results, highlighting stronger urban hotel performance, higher non-room revenue, active property conversions, and increased balance sheet flexibility from recent refinancing. See our latest analysis for RLJ Lodging Trust. At a share price of US$8.02, RLJ Lodging Trust has seen short term momentum pick up, with a 30 day share price return of 7.94% and a 90 day gain of 8.23%. This comes even...

In recent days, ZoomInfo Technologies reported that its upmarket customers now account for 74% of its business, Copilot AI has reached 20% of annual contract value, and the company approved an additional US$1.00 billion for share repurchases while providing cautious 2026 revenue guidance. At the same time, supportive comments from Nvidia CEO Jensen Huang about AI complementing enterprise software reframed how investors view ZoomInfo’s AI-focused evolution. We’ll now examine how Nvidia’s...

DoubleVerify Holdings (DV) has drawn fresh attention after unveiling a record US$300 million share repurchase program, even as its latest results showed softer revenue and earnings alongside moderate guidance for 2026. See our latest analysis for DoubleVerify Holdings. The buyback news arrived after a weak stretch, with the share price return down around 3% year to date and the 1 year total shareholder return down about 29%. However, the stock has bounced sharply in the last week as investors...

Option Care Health (OPCH) shares came into focus after the company reported fourth quarter and full year 2025 results, combining higher sales with margin pressure from biosimilar adoption, reaffirmed guidance and a larger share repurchase program. See our latest analysis for Option Care Health. At a share price of US$32.46, Option Care Health has seen pressure recently, with a 7 day share price return of a 10.06% decline and a 1 month share price return of a 4.53% decline. This is in contrast...

ESAB Corporation recently reported fourth-quarter 2025 results showing higher sales but lower earnings year-on-year, while its Board affirmed a quarterly cash dividend of US$0.10 per share payable on April 17, 2026. Alongside this, increased institutional ownership and the launch of the Ruffian EMP 270G welding generator signal growing interest in ESAB’s product portfolio and income-return profile. With ESAB maintaining its dividend and enhancing its welding offering, we’ll now examine how...

AerCap Holdings recently reported record quarterly net income and earnings per share, announced a new US$1.00 billion share repurchase program, and raised its 2026 quarterly dividend following strong full-year results. These moves, alongside a sharp increase in earnings guidance and growing institutional interest, highlight management’s confidence in AerCap’s cash generation and its emphasis on returning capital to shareholders. With AerCap’s sharply higher EPS guidance and larger dividend...

Visteon (VC) just packed several updates into its latest report, combining softer 2025 earnings, fresh 2026 sales guidance of US$3.625b to US$3.825b, a higher dividend, and a completed share repurchase program. See our latest analysis for Visteon. The latest report came with a sharp 3.1% one day share price decline and the stock now trades at US$95.67. However, a 14.3% one year total shareholder return contrasts with weaker three and five year total returns, hinting at recovering but...

What the latest 10-K and conference focus tell you about ServisFirst ServisFirst Bancshares (SFBS) recently filed its 2025 Form 10-K and featured at the 2026 Banking Outlook Conference, putting its capital strength, loan and deposit growth plans, and interest rate sensitivities in clear focus for investors. See our latest analysis for ServisFirst Bancshares. At a share price of US$81.01, ServisFirst has given investors a 14.42% 90 day share price return, even though the 1 year total...

Simpson Manufacturing recently detailed in its 2025 10-K that it has opened new production facilities in Columbus, Ohio, and Gallatin, Tennessee, while launching over 50 new products across wood, mass timber, and concrete construction categories. This combination of expanded in-house manufacturing and a broad wave of product development highlights how Simpson is reshaping its cost base and deepening its role in structural building solutions. Next, we’ll examine how these new Ohio and...

MoonLake Immunotherapeutics recently reported full-year 2025 results showing a wider net loss of US$227.32 million and a basic loss per share of US$3.53, while highlighting progress in developing its lead drug candidate, Sonelokimab (SLK), across several inflammatory disease indications. The company’s latest filings and updates emphasize FDA and EMA engagement, multiple positive late-stage trial readouts, and a planned SLK Biologics License Application submission in the second half of 2026...

ResMed (RMD) is expanding its U.S. footprint with a new distribution center in Greenwood, Indiana, planned to begin operations in 2027. The facility aims to widen North American coverage for its sleep and respiratory care products. See our latest analysis for ResMed. ResMed’s new Greenwood distribution hub comes as the stock has eased slightly in the short term, with a 7 day share price return showing a 1.74% decline, while longer term performance looks steadier, including a 1 year total...

In late February 2026, ACI Worldwide reported Q4 2025 revenue of US$481.6 million and full-year revenue of US$1.76 billion, alongside 2026 guidance calling for US$405–US$415 million in Q1 revenue and full-year revenue of US$1.88–US$1.91 billion, implying 7%–9% constant-currency growth. At the same time, ACI highlighted rapid adoption of its cloud-native Connetic platform, including a new UK retail bank deployment unifying major payment rails and AI-driven fraud prevention on a single...

Ingredion recently reported a softer fourth quarter for fiscal 2025, with revenue down year on year and its third consecutive quarter of net income and EPS declines, while also missing analysts’ EBITDA and adjusted operating income expectations. Soon after these results, President and CEO James P. Zallie was appointed Chairman following the former Chair’s resignation and sold 9,958 shares under a pre-set Rule 10b5-1 plan, sharpening investor attention on the company’s leadership and...